{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:30:24Z","timestamp":1783945824239,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:08:07Z","timestamp":1769713687000},"page":"e596-e602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pseudo-Richter Transformation Following BTKi Interruption in CLL: A Systematic Review of Clinical, Biological, and Pathologic Features"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-229X","authenticated-orcid":false,"given":"Javier","family":"Marco-Ayala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Garc\u00eda Malo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Ortu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3148-7037","authenticated-orcid":false,"given":"Mar\u00eda Luisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.01.010_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2023.101163","article-title":"Richter\u2019s transformation: transforming the clinical landscape","volume":"64","author":"Barrett","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2026.01.010_bib0002","article-title":"From genetics to therapy: unraveling the complexities of Richter transformation in chronic lymphocytic leukemia","volume":"120","author":"Abrisqueta","year":"2023","journal-title":"Cancer Treat Rev [Internet]"},{"issue":"6","key":"10.1016\/j.clml.2026.01.010_bib0003","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.01.010_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2022.829983","article-title":"Biology and treatment of Richter transformation","volume":"12","author":"Condoluci","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.01.010_bib0005","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2026.01.010_bib0006","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.mayocp.2024.01.015","article-title":"Pseudo-Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma after temporary acalabrutinib interruption","volume":"99","author":"Shi","year":"2024","journal-title":"Mayo Clinic Proce"},{"issue":"1","key":"10.1016\/j.clml.2026.01.010_bib0007","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jclinepi.2013.08.003","article-title":"The CARE guidelines: consensus-based clinical case report guideline development","volume":"67","author":"Gagnier","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clml.2026.01.010_bib0008","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.clml.2026.01.010_bib0009","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/bloodadvances.2020002454","article-title":"Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib","volume":"4","author":"Hampel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.01.010_bib0010","series-title":"Mayo Clinic Proceedings","first-page":"867","article-title":"Pseudo-Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma after temporary acalabrutinib interruption","volume":"99","author":"Shi","year":"2024"},{"issue":"2","key":"10.1016\/j.clml.2026.01.010_bib0011","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00428-025-04197-0","article-title":"Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP\/SH lymphoma workshop","volume":"487","author":"Anagnostopoulos","year":"2025","journal-title":"Virchows Archiv"},{"issue":"22","key":"10.1016\/j.clml.2026.01.010_bib0012","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.2019896688","article-title":"Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL","volume":"133","author":"Ahn","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.01.010_bib0013","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2026.01.010_bib0014","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 expression in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and large B-cell Richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"26","key":"10.1016\/j.clml.2026.01.010_bib0015","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Artmut","year":"2000","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2026.01.010_bib0016","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.3324\/haematol.2018.190132","article-title":"Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways","volume":"103","author":"Abruzzo","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.01.010_bib0017","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11899-023-00701-y","article-title":"Richter transformation of chronic lymphocytic leukemia\u2014are we making progress?","volume":"18","author":"Audil","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"10.1016\/j.clml.2026.01.010_bib0018","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1080\/10428194.2019.1602268","article-title":"Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice","volume":"60","author":"Hampel","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.clml.2026.01.010_bib0019","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1634\/theoncologist.2020-0388","article-title":"Disease flare during temporary interruption of Ibrutinib therapy in patients with chronic lymphocytic leukemia","volume":"25","author":"Hampel","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2026.01.010_bib0020","article-title":"Accelerated chronic lymphocytic leukaemia shows distinctive lymphocyte morphology in peripheral blood smears","author":"Aldinger","year":"2025","journal-title":"J Clin Pathol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:36:49Z","timestamp":1778067409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2152265026000248"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pseudo-Richter Transformation Following BTKi Interruption in CLL: A Systematic Review of Clinical, Biological, and Pathologic Features","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}